QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: GVP Module IX — Special Situations and Difficult Signals

Test your understanding of the concepts covered by GVP Module IX: Special Situations and Difficult Signals.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Report volume increases soon after a new indication and a formulation change. What should the signal assessment examine?

Only whether the number of reports increased Whether the change reflects altered exposure, population, formulation or prescribing circumstances rather than a true change in risk Whether all reports received before the changes should be excluded Whether the formulation change must be causal because it preceded the reports

Question 2 of 10 A database shows a sharp increase in a preferred term after a MedDRA version change and search-strategy modification. What should be done before interpreting the trend as a safety change?

Assume the product risk increased because the report count increased Ignore the trend because coding changes cannot affect signal detection Assess and document whether the methodological changes could explain part of the apparent increase Revert all cases to the previous coding without further analysis

Question 3 of 10 During review, a suspected product-specific signal is better explained by a manufacturing defect affecting several products. How should the record reflect this development?

Retain the original classification permanently for consistency Change the scientific description and management state while preserving traceability of historical decisions Delete the original signal so that the record reflects only the current view Treat the issue as resolved because it is no longer product-specific

Question 4 of 10 A company receives three well-documented reports of a rare, clinically distinctive syndrome with compatible timing and no obvious alternative cause. What is the most appropriate interpretation?

The signal should be closed because the number of cases is below a predefined threshold The signal may warrant substantial investigation despite limited statistical power The signal should be considered confirmed because the syndrome is rare The cases should be excluded because rare events cannot be assessed using pharmacovigilance data

Question 5 of 10 A publication reports a case series suggesting a product-event association. What is the correct treatment of the publication?

Treat publication in a peer-reviewed source as proof of causality Ignore it unless the same association appears in spontaneous-reporting statistics Evaluate the quality, relevance and limitations of the underlying evidence Give it less weight than all spontaneous reports because it is not regulatory data

Question 6 of 10 A signal remains inconclusive because the phenotype is poorly characterised. Which follow-up activity is most directly aligned with the information gap?

Request general additional data without defining an objective Conduct targeted follow-up to improve case characterisation and define what findings would change the assessment Close the signal because uncertainty is unavoidable Increase reporting volume without changing the information collected

Question 7 of 10 A post-authorisation comparative study identifies an elevated incidence estimate, although spontaneous reporting shows no disproportionality. Which conclusion is most appropriate?

The study cannot generate a signal without disproportionality The study finding may generate a signal and should be interpreted according to its design and research question The absence of disproportionality disproves the study finding The study automatically establishes a causal relationship

Question 8 of 10 A potentially fatal signal has incomplete evidence, but waiting for further confirmation could expose patients to avoidable harm. Which approach best reflects the article's framework?

Take no action until causality is established Escalate or communicate the concern while clearly distinguishing suspicion from established causality Treat the association as confirmed because the outcome is serious Lower the evidentiary standard and formally validate the signal immediately

Question 9 of 10 An adverse reaction is already listed, but a new cluster suggests a substantially shorter latency and greater severity in a particular population. What should the company do?

Close the signal because listedness prevents further signal management Assess whether the new characteristics materially change understanding or management of the risk Remove the event from signal review because it is already known Assume the finding is a class effect and take no product-specific action

Question 10 of 10 For a common event, which question is generally most relevant when assessing whether a new product-associated risk exists?

Whether the event appears in any case report at all Whether the observed frequency, severity, timing or phenotype differs from an appropriate background expectation Whether the event is already common in the general population Whether the event is listed for another product

QPPV.com

Knowledge Assessment: GVP Module IX — Special Situations and Difficult Signals

Cookie Settings